![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Weiss, Lena 
ORCID: https://orcid.org/0000-0002-8101-3529; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Stahler, Arndt ORCID: https://orcid.org/0000-0003-1041-0137; Westphalen, C. Benedikt ORCID: https://orcid.org/0000-0002-5310-3754; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Vehling-Kaiser, Ursula; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christian A.; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Holch, Julian Walter ORCID: https://orcid.org/0000-0002-4755-0179; Alig, Annabel ORCID: https://orcid.org/0000-0002-3922-3450; Jung, Andreas ORCID: https://orcid.org/0000-0001-5270-9108; Modest, Dominik Paul und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(15. Mai 2025):
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
In: European Journal of Cancer, Bd. 221, 115399
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-8101-3529; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Stahler, Arndt ORCID: https://orcid.org/0000-0003-1041-0137; Westphalen, C. Benedikt ORCID: https://orcid.org/0000-0002-5310-3754; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Vehling-Kaiser, Ursula; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christian A.; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Holch, Julian Walter ORCID: https://orcid.org/0000-0002-4755-0179; Alig, Annabel ORCID: https://orcid.org/0000-0002-3922-3450; Jung, Andreas ORCID: https://orcid.org/0000-0001-5270-9108; Modest, Dominik Paul und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(15. Mai 2025):
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
In: European Journal of Cancer, Bd. 221, 115399
[PDF, 1MB]
Weiss, Lena; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321; Fischer, Laura E.; Gieseler, Frank; Hoehler, Thomas; Mayerle, Julia ORCID: https://orcid.org/0000-0002-3666-6459; Quietzsch, Detlef; Reinacher-Schick, Anke; Schenk, Michael; Seipelt, Gernot; Siveke, Jens T.; Stahl, Michael; Vehling-Kaiser, Ursula; Waldschmidt, Dirk T.; Dorman, Klara; Zhang, Danmei; Westphalen, C. Benedikt ORCID: https://orcid.org/0000-0002-5310-3754; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, Stefan und Haas, Michael ORCID: https://orcid.org/0000-0001-6745-7177
(2023):
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
In: Clinical and Translational Oncology, Bd. 26, Nr. 5: S. 1268-1272
[PDF, 430kB]
ORCID: https://orcid.org/0000-0002-1349-3321; Fischer, Laura E.; Gieseler, Frank; Hoehler, Thomas; Mayerle, Julia ORCID: https://orcid.org/0000-0002-3666-6459; Quietzsch, Detlef; Reinacher-Schick, Anke; Schenk, Michael; Seipelt, Gernot; Siveke, Jens T.; Stahl, Michael; Vehling-Kaiser, Ursula; Waldschmidt, Dirk T.; Dorman, Klara; Zhang, Danmei; Westphalen, C. Benedikt ORCID: https://orcid.org/0000-0002-5310-3754; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, Stefan und Haas, Michael ORCID: https://orcid.org/0000-0001-6745-7177
(2023):
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
In: Clinical and Translational Oncology, Bd. 26, Nr. 5: S. 1268-1272
[PDF, 430kB]
Fischer, Laura E. ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christoph; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Held, Swantje; Miller-Phillips, Lisa; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas und Stintzing, Sebastian
(2020):
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
In: British Journal of Cancer, Bd. 124, Nr. 3: S. 587-594
Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker
(2017):
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925
Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2016):
Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).
In: Journal of Clinical Oncology, Bd. 34, Nr. 4
Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2016):
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434